He specializes in statistical methods for Bayesian clinical trial design and statistical methods for epigenetic studies. He has worked in the pharmaceutical drug developing industry on a wide range of clinical trials, including phase II dose-finding trails, confirmatory phase III trials, and integrated summaries of efficacy and safety (ISS/ISE). He actively collaborates with the United States Food and Drug Administration on statistical methods for Bayesian design of large-scale cardiovascular outcomes trials.